Home/Filings/4/0000950170-23-070382
4//SEC Filing

Sherman Matthew L 4

Accession 0000950170-23-070382

CIK 0001654151other

Filed

Dec 13, 7:00 PM ET

Accepted

Dec 14, 4:05 PM ET

Size

6.5 KB

Accession

0000950170-23-070382

Insider Transaction Report

Form 4
Period: 2023-12-12
Sherman Matthew L
EVP & Chief Medical Officer
Transactions
  • Award

    Common Stock

    2023-12-12+8,24499,306 total
  • Sale

    Common Stock

    2023-12-13$15.37/sh2,792$42,90596,514 total
Footnotes (3)
  • [F1]On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On December 12, 2023, the Issuer's Compensation Committee confirmed that performance criteria one had been met, resulting in the vesting of 8,244 RSUs.
  • [F2]Includes 434 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2023.
  • [F3]This sale was to cover tax liabilities in the vesting of RSUs.

Documents

1 file

Issuer

Deciphera Pharmaceuticals, Inc.

CIK 0001654151

Entity typeother

Related Parties

1
  • filerCIK 0001325710

Filing Metadata

Form type
4
Filed
Dec 13, 7:00 PM ET
Accepted
Dec 14, 4:05 PM ET
Size
6.5 KB